Tvardi Therapeutics
TVRD
33 hedge funds and large institutions have $3.21M invested in Tvardi Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 13 closing their positions.
3.95% more ownership
Funds ownership: 0.67% → 4.62% (+4%)
23% less funds holding
Funds holding: 43 → 33 (-10)
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
51% less capital invested
Capital invested by funds: $6.59M → $3.21M (-$3.38M)
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$134K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$55.4K |
| 3 |
AAP
Arax Advisory Partners
Denver,
Colorado
|
+$10.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.47K |
| 5 |
JP Morgan Chase
New York
|
+$468 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rockefeller Capital Management
New York
|
-$953K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$721K |
| 3 |
SC
Shay Capital
New York
|
-$524K |
| 4 |
CRC
Curi RMB Capital
Chicago,
Illinois
|
-$277K |
| 5 |
Millennium Management
New York
|
-$111K |
TVRD Hedge Fund Activity: Q1 2025 in Review
33 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2025, worth a combined $3.21M — down 51% from $6.59M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TVRD and 3 opened new positions — a net loss of 10 holders — while 12 trimmed existing stakes and 7 added.
The largest buyer was Bank of America, adding an estimated $134K. The largest seller was Rockefeller Capital Management, exiting entirely with an estimated $953K sold.
- 33 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2025, down from 43 in Q4 2024.
- Funds reported $3.21M of Tvardi Therapeutics stock for Q1 2025, down 51% quarter-over-quarter.
- 3 funds opened new Tvardi Therapeutics positions in Q1 2025 and 13 closed out, a net change of -10 holders.
- The largest Tvardi Therapeutics buyer in Q1 2025 was Bank of America, an estimated $134K added.
- The largest Tvardi Therapeutics seller in Q1 2025 was Rockefeller Capital Management, an estimated $953K sold.
Based on aggregated 13F filings for Q1 2025.